Publications

Dalbavancin Activity Tested Against Rarely Isolated Gram-positive Organism Species from Europe, Lead author: Jones RN, presented at 17th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2007, Munich, Germany

Antimicrobial Activity of Tigecycyline (TGC) Tested Against Contemporary Bacterial Isolates Collected in European Hospitals, Lead author: Jones RN, presented at 6th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 7 – 9, 2007, Raffles City Convention Center, Singapore

Activity of Tigecycline (TGC) When Tested Against Gram-positive (GP) Pathogens in North American (NA) Hospitals (2006), Lead author: Jones RN, presented at 6th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 7 – 9, 2007, Raffles City Convention Center, Singapore

Activity of ceftobiprole tested against staphylococci and streptococci in the Asia-Pacific region: Report from the SENTRY Antimicrobial Surveillance Program (2006), Lead author: Bell JM, presented at 6th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 7 – 9, 2007, Raffles City Convention Center, Singapore

Doripenem (DOR) activity against leading bacterial pathogens in the Asia-Pacific region: Report from the SENTRY Antimicrobial Surveillance Program, 2006, Lead author: Bell JM, presented at 6th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 7 – 9, 2007, Raffles City Convention Center, Singapore

Tigecycline Antimicrobial Susceptibility Testing in the Asia-Pacific (APAC) Region: Report from the SENTRY Antimicrobial Surveillance Program (2006), Lead author: Bell JM, presented at 6th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 7 – 9, 2007, Raffles City Convention Center, Singapore

Tigecycline (TGC) Potency and Spectrum When Tested Against Gram-negative Pathogens from North American Medical Centers (2006), Lead author: Jones RN, presented at 6th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 7 – 9, 2007, Raffles City Convention Center, Singapore

Activity of meropenem as serine carbapenamases evolve in US medical centers: Monitoring report from the MYSTIC Program (2006). by Rhomberg PR, Deshpande LM, Kirby JT and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 59 (4): 425-432

Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. by Jones RN, Sader HS, Fritsche TR and Janechek MJ published in Diagn. Microbiol. Infect. Dis. 2007; 59 (4): 467-472

Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin structure infections. by Sader HS, Mallick R, Kuznik A, Fritsche TR and Jones RN published in Int. J. Antimicrob Agents 2007; 30 (6): 514-520

LEADER surveillance program results for 2006: An activity and spectrum of linezolid using clinical isolates from the United States (50 medical centers). by Jones RN, Fritsche TR, Sader HS and Ross JE published in Diagn. Microbiol. Infect. Dis. 2007; 59 (3): 309-317

Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent. by Rennie RP, Koeth L, Jones RN, Fritsche TR, Knapp CC, Killian SB and Goldstein BP published in J. Clin. Microbiol. 2007; 45 (10): 3151-3154

Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: Toward endemicity? by Tato M, Coque TM, Ruiz-Garbajosa P, Pintado V, Cobo J, Sader HS, Jones RN, Baquero F and Canton R published in Clin. Infect. Dis. 2007; 45 (9): 1171-1178

Zyvox® Annual Appraisal of Potency and Spectrum Program results for 2006: An activity and spectrum analysis of linezolid using clinical isolates from 16 countries. by Jones RN, Fritsche TR, Sader HS and Ross JE published in Diagn. Microbiol. Infect. Dis. 2007; 59 (2): 199-209

Molecular characterization of Staphylococcus aureus isolates from a 2005 clinical trial of uncomplicated skin and skin structure infections. by Jones RN, Nilius AM, Akinlade BK, Deshpande LM and Notario GF published in Antimicrob. Agents Chemother. 2007; 51 (9): 3381-3384

Evaluation of the susceptibility profiles, genetic similarity and presence of qnr gene in Escherichia coli resistant to ciprofloxacin isoalted in Brazilian Hospitals. by Pereira AS, Andrade SS, Monteiro J, Sader HS, Pignatari ACC and Gales AC published in Braz. J. Inf. Dis. 2007; 11 (11): 40-43

Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae. by Lodise TP, Nau R, Kinzig M, Jones RN, Drusano GL and Sorgel F published in Diagn. Microbiol. Infect. Dis. 2007; 58 (4): 445-452

Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin and teicoplanin: A SENTRY Program report (2003-2004). by Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN and Turnidge JD published in Int. J. Antimicrob. Agents 2007; 30 (2): 143-149

In71, an Enterobacter cloacae bla_VIM-1-carrying integron related to In70.2 from Italian Pseudomonas aeruginosa isolates: A SENTRY Antimicrobial Surveillance Program report. by Castanheira M, Sader HS, Jones RN, Debbia Eugenio, Picao RC and Gales AC published in Microb. Drug Resis. 2007; 13 (2): 130-134

Characterization of an integron carrying bla_IMP-1 and a new aminoglycoside resistance gene aac(6′)-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. by Mendes RE, Castanheira M, Toleman MA, Sader HS, Jones RN and Walsh TR published in Antimicrob. Agents Chemother. 2007; 51 (7): 2611-2614

Development of anidulafungin for disk diffusion susceptibility testing against Candida spp. by Jones RN, Kirby JT, Messer SA and Sheehan DJ published in Diagn. Microbiol. Infect. Dis. 2007; 58 (3): 371-374

Tigecycline disk diffusion breakpoints of Acinetobacter spp.: A clinical point of view. by Curcio D, Fernandez F, Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC and Sader HS published in J. Clin. Microbiol. 2007; 45 (6): 2095-2096

Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: A report from the SENTRY Antimicrobial Surveillance Program. by Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 58: 163-170

Daptomycin antimicrobial activity tested against methicillin-resistant staphylococi and vancomycin-resistant enterococci isolated in European medical centers (2005). by Sader HS, Watters AA, Fritsche TR and Jones RN published in BMC Infect. Dis. 2007; 7 (1) : 29

Comment on: Occurrence prevalence and genetic environment of CTX-M beta-lactamases in Enterobacteriaceae from Indian hospitals. by Walsh TR, Toleman MA and Jones RN published in J. Antimicrob. Chemother. 2007; 59 (4): 799-800

Accuracies of beta-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek and Vitek 2). by Juretschko S, LaBombardi VJ, Lerner SA and Schreckenberger PC published in J. Clin. Microbiol. 2007; 45 (4): 1339-1342

Influence of polysorbate-80 when determining the tigecycline MIC by the reference method. by Jones RN, Knapp CC and Dowzicky MJ published in Diagn. Microbiol. Infect. Dis. 2007; 58 (1): 145-146

Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. by Jones RN, Fritsche TR, Sader HS and Stilwell MG published in Diagn. Microbiol. Infect. Dis. 2007; 58 (1): 9-17

Garenoxacin activity against isolates from patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae. by Jones RN, Sader HS, Stilwell MG and Fritsche TR published in Diagn. Microbiol. Infect. Dis. 2007; 58 (1): 1-7

Potency and spectrum of garenoxacin tested against an international collection of skin and skin tissue infection pathogens: Report from the SENTRY Antimicrobial Surveillance Program (1999-2004). by Fritsche TR, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 58 (1): 19-26

In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004). by Sader HS, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 58 (1): 27-32

Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test reslt for isolates of Escherichia coli and Klebsiella pneumoniae: Results from the SENTRY Asia-Pacific Surveillance Program. by Bell JM, Chitsaz M, Turnidge JD, Barton M, walters LJ and Jones RN published in J. Clin. Microbiol. 2007; 45 (5): 1478-1482

Reevaluation of Clinical and Laboratory Standards Institute disk diffusion breakpoints for tetracyclines for testing Enterobacteriaceae. by Sader HS, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM and Jones RN published in J. Clin. Microbiol. 2007; 45 (5): 1640-1643

Impact of drug-exposure intensity and duration of therapy on the emergence Staphylococcus aureus resistance to a quinolone antimicrobial. by Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L, Leary R, Jones RN and Drusano GL published in J. Infect. Dis. 2007; 195 (12): 1818-1827

Evaluation of the in vitro activity of daptomycin against 19,615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). by Pfaller MA, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 57 (4): 459-465

Re-evaluation of the role of broad spectrum cephalosporins against staphylococci by applying contemporary in vitro results and pharmacokinetic/pharmacodynamic principles. by Sader HS, Bhavnani SM, Ambrose PG, Jones RN and Pfaller MA published in J. Chemother. 2007; 19 (1): 38-43

Oral β-lactams applied to uncomplicated infections of skin and skin structures. by Jacobs MR, Jones RN and Giordano PA published in Diagn. Microbiol. Infect. Dis. 2007; 57 (Suppl 3): 55S-65S

Activity of linezolid against 3,251 strains of uncommonly isolated Gram-positive organisms: Report from the SENTRY Antimicrobial Surveillance Program. by Jones RN, Stilwell MG, Hogan PA and Sheehan DJ published in Antimicrob. Agents Chemother. 2007; 51 (4): 1491-1493

Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. by Toleman MA, Bennett PM, Bennett DMC, Jones RN and Walsh TR published in Emerg. Inf. Dis. 2007; 13 (4): 559-565

Activity of dalbavancin tested against Staphylococcus spp. and β-haemolytic Staphylococcus spp. isolated from 52 geographically diverse medical centers in the United States. by Biedenbach DJ, Ross JE, Fritsche TR, Sader HS and Jones RN published in J. Clin. Microbiol. 2007; 45 (3): 998-1004

Bactericidal activity of cefepime and ceftriaxone tested against Streptococcus pneumoniae. by Pottumarthy S, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 57 (3): 345-349

Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. by Sader HS, Hsiung A, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 57 (3): 341-344

Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci. by Moet GJ, Dowzicky MJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 57 (3): 333-336

Oxazolidinone susceptibility patterns for 2005: International report from the Zyvox®; Annual Appraisal of Potency and Spectrum Study. by Ross JE, Fritsche TR, Sader HS and Jones RN published in Int. J. Antimicrob. Agents 2007; 29 (3): 295-301

bla_VIM-2 and bla_VIM-7 carbapenemase-producing Pseudomonas aeruginosa isolates detected in a tertiary care medical center in the United States: Report from the MYSTIC Program. by Aboufaycal H, Sader HS, Deshpande LM, Toleman M, Bodey G, Raad I and Jones RN published in J. Clin. Microbiol. 2007; 45: 614-615

Cefdinir: An oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections. by Sader HS and Jones RN published in Expert Rev. Anti. Infect. Ther. 2007; 5 (1): 29-43

Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC Program report from the Unite States component (2005). by Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 57 (2): 207-215

Multicenter studies of tigecycline disk diffusions susceptibility results for Acinetobacter spp. by Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM and Sader HS published in J. Clin. Microbiol. 2007; 45 (1): 227-230

Contemporary causes of skin and soft tissue infections in North America, Latin America and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004). by Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG and Fritsche TR published in Diagn. Microbiol. Infect. Dis. 2007; 57 (1): 7-13

Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004). by Jones RN, Sader HS, Fritsche TR and Pottumarthy S published in Diagn. Microbiol. Infect. Dis. 2007; 57 (1): 109-116